Considerable controversy exists over the purported role of obesity in causing hyperglycemia, hyperlipemia, hyperinsulinemia, and insulin resistance; and the potential beneficial effects of weight reduction remain incompletely defined. Hypertriglyceridemia is one of the metabolic abnormalities proposed to accompany obesity, and in order to help explain the mechanisms leading to this abnormality we have proposed the following sequential hypothesis: insulin resistance ® hyperinsulinemia ® accelerated hepatic triglyceride(TG) production ® elevated plasma TG concentrations. To test this hypothesis and to gain insight into both the possible role of obesity in causing the above metabolic abnormalities and the potential benefit of weight reduction we studied the effects of weight loss on various aspects of carbohydrate and lipid metabolism in a group of 36 normal and hyperlipoproteinemic subjects. Only weak to absent correlations (r = 0.03 -0.46) were noted between obesity and the metabolic variables measured. This points out that in our study group obesity cannot be the sole, or even the major, cause of these abnormalities in the first place. Further, we have observed marked decreases after weight reduction in fasting plasma TG (mean value: pre-weight reduction, 319 mg/100 ml; post-weight reduction, 180 mg/100 ml) and cholesterol (mean values: pre-weight reduction, 282 mg/100 ml; post-weight reduction, 223 mg/100 ml) levels, with a direct relationship between the magnitude of the fall in plasma […] after weight reduction were also measured and the overall post-weight reduction decrease in insulin response was 48% while the glucose response was relatively unchanged. In a subgroup of patients we studied both the degree of cellular insulin resistance and the rate of hepatic very low density (VLDL) TG production before and after weight reduction. These subjects demonstrated significant decreases after weight reduction in both degree of insulin resistance (33% decrease) and VLDL-TG production rates (40% decrease). Thus, weight reduction has lowered each of the antecedent variables (insulin resistance, hyperinsulinemia, and VLDL-TG production) that according to the above hypothesis lead to hypertriglyceridemia, and we believe the overall scheme is greatly strengthened. Furthermore, the consistent decreases in plasma TG and cholesterol levels seen in all subjects lead us to conclude that weight reduction is an important therapeutic modality for patients with endogenous hypertriglyceridemia.
A B S T R A C T Considerable controversy exists over the purported role of obesity in causing hyperglycemia, hyperlipemia, hyperinsulinemia, and insulin resistance; and the potential beneficial effects of weight reduction remain incompletely defined. Hypertriglyceridemia is one of the metabolic, abnormalities proposed to accompany obesity, and in order to help explain the mechanisms leading to this abnormality we have proposed the following sequential hypothesis: insulin resistance > hyperinsulinemia > accelerated hepatic triglyceride (TG) production > elevated plasma TG concentrations. To test this hypothesis and to gain insight into both the possible role of obesity in causing the above metabolic abnormalities and the potential benefit of weight reduction we studied the effects of weight loss on various aspects of carbohydrate and lipid metabolism in a group of 36 normal and hyperlipoproteinemic subjects. Only weak to absent correlations (r = 0.03 -0. 46) were noted between obesity and the metabolic variables measured. This points out that in our study group obesity cannot be the sole, or even the major, cause of these abnormalities in the first place. Further, we have observed marked decreases after weight reduction in fasting plasma TG (mean value: pre-weight reduction, 319 mg/l00 ml; post-weight reduction, 180 mg/100 ml) and cholesterol (mean values: pre-weight reduction, 282 mg/100 ml; post-weight reduction, 223 mg/100 ml) levels, with a direct relationship between the magnitude of the fall in plasma lipid values and the height of the initial plasma TG level. We have also noted significant Dr. Olefsky is a Research and Education Associate, Veterans Administration.
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decreases after weight reduction in the insulin and glucose responses during the oral glucose tolerance test (37% decrease and 12% decrease, respectively). Insulin and glucose responses to liquid food before and after weight reduction were also measured and the overall post-weight reduction decrease in insulin response was 48% while the glucose response was relatively unchanged. In a subgroup of patients we studied both the degree of cellular insulin resistance and the rate of hepatic very low density (VLDL) TG production before and after weight reduction. These subjects demonstrated significant decreases after weight reduction in both degree of insulin resistance (33% decrease) and VLDL-TG production rates (40% decrease). Thus, INTRODUCTION It has been suggested that obesity has an important causal role in the development of hyperglycemia (1) , hyperlipemia (2, 3) , hyperinsulinemia (4) , and insulin resistance (5) . However, considerable controversy still exists over the role of obesity in causing the above metabolic abnormalities (6) (7) (8) (9) (10) , and the mechanisms involved remain quite unclear. Furthermore, although it it commonly accepted that weight loss by obese subjects ameliorates these abnormalities (11) (12) FIGURE 1 Schematic representation of a sequential hypothesis relating insulin resistance to hyperinsulinemia and subsequent hypertriglyceridemia.
Most of the reports to date have involved only a few patients (13) (14) (15) (16) (17) (18) , and have not examined a wide spectrum of variables (14, 15, 18, 19) . Furthermore, even if weight loss does lead to a decrease in hyperglycemia, hyperlipemia, hyperinsulinemia, and insulin resistance, this does not necessarily mean that obesity was the sole cause of these metabolic abnormalities in the first place. For these reasons, and because hyperglycemia (20) and hyperlipemia (21, 22) have been proposed as independent risk factors for the development of coronary heart disease, it seemed important to evaluate the relationship between obesity and various aspects of carbohydrate and lipid metabolism in a large group of normal and hyperlipoproteinemic subjects with varying degrees of obesity; and then to study the effects of weight loss on these variables in the same group of patients.
Plasma triglyceride (TG)' concentration is one of the metabolic variables we have measured. To help explain the mechanism leading to hypertriglyceridemia, we have previously proposed a sequential hypothesis ( Fig. 1 ) that states that tissue resistance to insulinmediated glucose uptake is a common underlying finding in most patients with endogenous hypertriglyceridemia, and that in an effort to maintain glucose homeostasis, insulin-resistant subjects secrete increased amounts of insulin (23, 24) . We have also suggested that this byperinsulinemnia may act upon the liver to accelerate very low density lipoprotein (VLDL) TG production rate, which in turn leads to endogenous hypertriglyceridemia (10, 24, 25) . The term "endogenous hypertriglyceridemnia" corresponds to the primary hyperlipoproteinemias recently defined as types JIb, III, and IV (26) . A way to help validate a three-part sequential hypothesis such as this would be to perturb the system and measure the effects of this perturbation on each step of the sequence. If all the changes were in the predicted direc-tion, then the hypothesis would be strengthened, whereas, if one observed a dissociation in the direction of the predicted changes, the argument would be weakened. To test our hypothesis in this manner, and to gain clinical insight into the possible beneficial effects of weight loss, we have studied the metabolic effects of weight reduction in 36 patients.
METHODS
Subjects 36 subjects selected from Stanford's Nutrition and Metabolism Clinic underwent a mean weight loss of 10.9 kg (range 9.1-14.2 kg). The only criteria for selection was the subject's acquisition of more than 10 kg in body weight since age 20 and the subject's willingness to undertake a weight reduction program. Tables I and II list the clinical characteristics and metabolic data of our study group before and after weight reduction. None of our patients were massively obese and the degree of obesity of these patients is similar to the degree of moderate obesity commonly encountered by a physician. By weight history all of them had acquired the bulk of their excess poundage in adulthood. Percentage adiposity was determined according tothe anthropometric technique of Steinkamp et al. (27) . With (29, 30) . The formula provided 251 mg cholesterol for every 1021 cal and was consumed daily in four equal feedings. Each feeding was ingested evenly and slowly over a 30-min period. Oral glucose tolerance test, fasting plasma TG and cholesterol measurements, and plasma lipoprotein electrophoresis were performed as was done in the outpatient subjects. Additional studies were performed on these inpatient subjects as follows:
Studies of glucose and insulin responses to formiula. On two separate occasions during each hospitalization, plasma was sampled for insulin and glucose just before the 11 a.m. feeding, and again at 12, 1 and 2 p.m. The data are expressed as the mean values of these two studies for each subject.
VLDL-TG production rate studies. This was done according to a previously reported method (25, 31) , which is briefly summarized as follows: [3H]glycerol is injected intravenously and becomes incorporated into plasma VLDL-TG molecules. The specific activity decay curve of the endogenously labeled VLDL-TG is measured, and from this curve, the fractional loss rate of the labeled VLDL-TG is calculated. If one assumes plasma volume to be 4.5% of body weight, then the VLDL-TG pool size can be calculated according to the following formula: VLDL-TG pool size 4.5% X kg body weight X VLDL-TG concentration.
Finally, the product of the fractional loss rate and VLDL-TG pool size equals the VLDL-TG removal rate (mg/ kg/h). Since the VLDL-TG concentration is in a steady state throughout the study, the VLDL-TG removal rate is equal to the VLDL-TG production rate (25, 31) .
Estimate of insulin resistance (or impedance). The method for estimating this variable has been previously reported (23) , and the insulin resistance measured by this technique should not be confused with the type of insulin resistance sometimes found in insulin-treated diabetics who develop excessive amounts of anti-insulin antibodies. For this reason we have proposed the term impedance to describe this type of insulin-resistant state and we will use these two terms interchangeably in this report. This study is performed by simultaneously infusing constant amounts of crystalline pork insulin (50 mU/min), glucose (6 mg/ kg/min), epinephrine (6 /Ag/min), and propranolol (0.08 mg/min). The infusion is begun 5 min after a 5-mg loading dose of propranolol, and is constantly administered via a Harvard pump (Harvard Apparatus Co., Inc., Millis, Mass.) over a period of 150 min. Steady state plasma concentrations of insulin and glucose are achieved within 90 min after the start of the infusion, and we then measure these levels every 10 min for an additional 60 min. Insulin resistance is expressed as the mean of the seven steady state plasma glucose levels (SSPG). This approach is based upon the known ability of epinephrine and propranolol to suppress endogenous insulin secretion (32) . Confirmation of this action under these particular experimental conditions has been obtained by finding no rise in plasma endogenous insulin levels during extreme hyperglycemia after an infusion of glucose, epinephrine, and propranolol (23 (37) .
Statistical methods T tests were performed by the two-tailed, paired Student's t test (38) . Simple correlation coefficients were calculated by the product-moment correlation method (38) . Partial correlation coefficients were calculated by the use of multiple regression analysis (38 Table IV presents the data for the cross-correlations among the metabolic variables themselves in the entire group. As predicted by our hypothesis (Fig. 1 ) a highly significant correlation is noted between fasting TG level and both fasting insulin level and insulin response.
Next, we looked at the effects of weight loss on the metabolic variables in question. Fig. 2 summarizes the effects of weight reduction on plasma TG and cholesterol levels. The mean cholesterol and TG levels for each patient were determined before and after weight loss from a minimum of two samples at each stage, and The decreases in both plasma TG (from 319 mg/100 ml to 180 mg/100 ml) and plasma cholesterol levels (from 282 mg/100 ml to 223 mg/100 ml) are both considerable in magnitude and highly significant (P < 0.0001). Furthermore, the TG levels of 34 out of 36 subjects and the cholesterol levels of 33 out of 36 subjects fell after weight loss.
To illustrate the magnitude of the post-weight reduction fall in plasma TG and cholesterol in relation to the pre-weight reduction plasma TG level, the patients were divided into quartiles on the basis of their preweight reduction plasma TG concentrations (Table V) . The average amount of weight loss was the same in all four groups. Going from the lowest to highest quartile the mean decreases in plasma TG level after weight loss were 19 mg/100 ml, 43 mg/100 ml, 140 mg/100 ml, and 347 mg/100 ml. The mean post-weight reduction fall in cholesterol levels showed the same trend with decreases of 24 mg/100 ml, 46 mg/100 ml, 71 mg/100 ml, and 101 mg/100 ml, going from the lowest to highest pre-weight reduction TG quartiles. Thus, the greater the pre-weight reduction plasma TG level, the greater the decrease in plasma TG and cholesterol concentration in both percentage and absolute terms.
The mean plasma insulin and glucose responses during the oral glucose tolerance test before and after weight reduction are shown in Fig. 3 . The mean insulin values after weight loss are lower at every time interval (3B) and these differences are statistically significant at 30, 60, 120, and 180 min (an overall 37% decrease in area under the curve). Although not as impressive as the lowering of insulin responses after weight loss, the mean glucose responses are also lower after weight loss (3A), and these differences reach statistical significance at each time point (an overall 12% decrease in area under the curve). Thus, the insulin decrement was approximately three times the glucose decrement. After weight loss, the insulin response to oral glucose decreased in 34 out of 36 subjects and glucose response decreased in 31 out of 36 subjects.
Additionally, the plasma glucose and insulin responses to the 11 a.m. liquid food ingestion were studied in nine inpatient subjects before and after weight loss. These data are presented in Fig. 4 , and it can be seen that a post-weight reduction fall in insulin response is quite evident with significant differences noted at each time point (4B). Furthermore, the insulin response to formula Of the nine subjects in the 1st quartile, six were classified as normal, and three had Type Ila hyperlipoproteinemia.
Of the nine subjects in the 2nd quartile, one was classified as Type Ila, three as Type TIb, and five as Type IV,
Of the nine subjects in the 3rd quartile, three were classified as Type Ilb, one as Type III, and five as Type IV.
Of the nine subjects in the 4th quartile, two were classified as Type III and seven as Type IV. I I I~~~~~~~~~~~ FIGURE 6 VLDL-TG production rates in 13 patients before and after weight reduction. The lines connect each patient's before and after value. Data are given as means+SEM.
subjects after weight loss. Fig. 5B compares the mean steady state plasma insulin levels during these infusion studies for the group before and after weight loss. No significant differences exist between these two mean values, and thus changes in SSPG levels cannot be attributed to changes in concomitant steady state plasma insulin values. According to our previously outlined sequential hypothesis, the decreases in glucose and insulin responses to oral glucose that we have shown in the larger group of 36 patients can be attributed to the decreases in degree of insulin resistance which we have demonstrated in the inpatient studies.
In order to further delineate the mechanism(s) responsible for the fall in plasma TG concentrations after weight loss, VLDL-TG production rates were determined in 13 subjects before and after weight reduction. The results of these studies are displayed in Fig. 6 . VLDL-TG production rates decreased in 11 out of 13 subjects after weight loss, resulting in a mean VLDL-TG production rate before weight loss of 15.9±1.9 mg/kg/h and a mean production rate afterward of 9.6±+1.3 mg/ kg/h. These differences are significant at the P < 0.001 level.
Table VI presents the correlation coefficients among the metabolic variables measured in the inpatient subgroup. A significant correlation exists between degree (r = 0.57). Furthermore, insulin response is highly correlated to VLDL-TG production rate (r 0.65) and VLDL-TG production rate is closely correlated to fasting TG concentration (r = 0.82). Thus, these correlations offer support for each of the direct individual steps of the hypothesis outlined in Fig. 1 . The correlation. coefficient between insulin resistance and VLDL-TG production rate is r 0.72, P < 0.05 (not shown in Table VI). Although this finding further supports our hyl)othesis, both of these measurements were made on only seven subjects; consequently due to the small number of observations this correlation just reaches statistical significance and we are reluctant to stress this relationship.
To emphasize the dramatic effects of weight loss, we summarized (Table VII) the data on the glucose responses, insulin responses, and fasting plasma TG and cholesterol levels in the five most obese and five least obese males as determined by their preweight reduction percent adiposity. It can be seen that comparable amounts of weight loss resulted in similar decrements in these variables in the two groups despite a markedly different pre-weight reduction degree of obesity. It (27) , while most of the above authors use relative weight. However, using relative weight as the estimate of obesity did not alter any of our findings (Table III) reduction decrements in plasma TG and cholesterol concentrations in both percentage and absolute terms. Furthermore, we have observed significant post-weight reduction decreases in both glucose and insulin responses to oral glucose, with the decreases in insulin response being considerably greater. All of these changes occurred after modest amounts of weight loss. The data were collected during states of weight stability before and after the weight reduction periods, so that any metabolic changes we detected could reasonably be attributed to weight loss alone. The post-weight reduction diet was identical in proportion of food constituents to the preweight reduction diet and differed only in total caloric content, since fewer total calories were necessary to maintain isocaioric conditions at the reduced body weight. It should be noted that during the period of hypocaloric intake the percentage of calories derived from carbohydrate was unchanged. Thus, carbohydrate restriction. was proportionate to total caloric restriction, and consequently the degree of carbohydrate restriction varied only inasmuch as total caloric restriction varied. This design does not permit conclusions as to the specific metabolic effects of carbohydrate restriction alone, but we attempted to avoid any possible effects of carbohydrate restriction per se by collecting the postweight reduction data after the 2 wk stabilization period.
Since the glucose challenges were administered on the basis of body size it should be pointed out that in no case was the post-weight reduction administered glucose load less than 90% of the original challenge. For example, a decrease in weight of 11 kg (the mean weight loss of our group) would result in -only a 4 g decrease in glucose load during the oral glucose tolerance test (i.e., a 5'10" 200-lbs subject receives 84 g of glucose while a 5'10" 177-lbs subject receives 80 g of glucose We have previously proposed an hypothesis to help explain one of the mechanisms causing endogenous hypertriglyceridemia (primary Types IIb, III, and IV) in man. We have suggested that a basic underlying abnormality is impedance or resistance to insulin-mediated glucose uptake at the cellular level (23) . It was our postulate that in order to maintain glucose homeostasis, insulin-resistant individuals secrete increased amounts of insulin that accelerate the hepatic VLDL-TG production rate, which in turn leads to hypertriglyceridemia (10, 24, 25) . The significant correlations noted in this study between degree of insulin resistance and insulin response, insulin response and VLDL-TG production rate, and VLDL-TG production rate and fasting TG concentration in the inpatient subgroup, and between group support each step of this scheme (Fig. 1) . To help confirm this sequential hypothesis, we have turned insulin response and TG concentration in the entire to a principle often used to establish causal relationships in complex multivariable systems. We have perturbed the system, thus allowing greater insight than is allowed in static situations. Also, by focusing on intraindividual comparisons this study design avoids the confounding effect of excessive interindividual variation when seeking relationships between biologic variables. After the perturbation of weight loss, we observed decreases in both plasma TG concentration and the glucose and insulin responses to oral glucose. Our inpatient studies were designed to uncover the mechanisms behind these changes, and these inpatient studies revealed marked decreases in both degree of insulin resistance and VLDL-TG production rates after weight loss. According to the sequence outlined in Fig. 1 While these findings are simply associations, and by themselves do not prove causality, we believe that since weight reduction lowered all three of the supposed antecedent variables, which according to our hypothesis, lead to increased plasma TG concentration (i.e., insulin resistance, plasma insulin concentration, and VLDL-TG production rate) the overall validity of the hypothesis is strengthened. We believe this hypothesis applies to the great majority of patients with endogenous hypertriglyceridemia. However, it should be pointed out that increased insulin levels are not present in all cases of hypertriglyceridemia. For example, many ketosis-prone diabetic patients with severe insulin deficiency develop increased TG levels, which obviously cannot be related to hyperinsulinemia.
Lastly, one may speculate as to why an average weight loss of only 11 kg leads to the rather sizable metabolic changes we have observed. In a study such as ours, which compares each individual to himself, the effects of excessive interindividual biologic variability tend to dampen out. This gives greater leverage to the variable allowed to change (in this study weight alone) and its effects are easier to detect. Thus, we believe that obesity is one of a variety of factors that influence the metabolic variables measured, and that this influence is amplified by our study design. The mechanisms by which weight loss initiates the changes we have observed remain unclear. Acquired weight gain has been associated with enlarged adipocytes, and Salans, Knittle, and Hirsch (44) have shown enlarged adipocytes to be insulin-resistant. One might reason then that post-weight reduction decreases in insulin and glucose responses are simply due to the decrease in mass of insulin-resistant adipose tissue. However, Bjorntorp, Krotkiewski, Larsson, and Solmo-Szucs, and Bjorntorp, Berchtold, Holm, and Larsson have pointed out that adipose tissue appears to account for less than 5% of an individual's total glucose consumption (45, 46) , and thus, modest changes in the amount of adipose tissue present are not likely to appreciably affect the body's overall insulin and glucose economy. It is obvious, then, that further information is needed before a mechanism can be suggested whereby modest decreases in weight can initiate profound changes in the metabolic sequence we have described.
Whatever the mechanism, these studies clearly demonstrate the potent beneficial effects of modest amounts of weight reduction in patients with varying degrees of obesity on some of the known metabolic cardiovascular risk factors.
